Skip to content
lifestyle.the-newshub.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Absci Corporation
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
September 24, 2026
Absci to Participate in Upcoming Investor Conferences
September 1, 2026
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
August 12, 2026
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
July 14, 2026
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
June 24, 2026
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
June 24, 2026
Absci to Participate in Upcoming Investor Conferences
May 30, 2026
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 27, 2026
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
May 26, 2026
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
May 24, 2026
1
2
Next Page
→